MoonLake Immunotherapeutics Files 2024 10-K
Ticker: MLTX · Form: 10-K · Filed: Feb 26, 2025 · CIK: 1821586
| Field | Detail |
|---|---|
| Company | Moonlake Immunotherapeutics (MLTX) |
| Form Type | 10-K |
| Filed Date | Feb 26, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, annual-report
TL;DR
MoonLake filed its 2024 10-K. Pharma biz. Check financials.
AI Summary
MoonLake Immunotherapeutics filed its 2024 10-K on February 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Helix Acquisition Corp, is focused on pharmaceutical preparations. Key personnel mentioned include Dr. Kristian Reich. Financial details and specific business segments are not detailed in this excerpt.
Why It Matters
This filing provides a comprehensive overview of MoonLake Immunotherapeutics' financial health and business operations for the fiscal year 2024, crucial for investors and stakeholders to assess performance and future outlook.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, MoonLake Immunotherapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- 2024 — Fiscal Year (Reporting period for the 10-K)
- 2023 — Previous Fiscal Year (For comparative financial analysis)
Key Players & Entities
- MoonLake Immunotherapeutics (company) — Filer of the 10-K
- Helix Acquisition Corp (company) — Former name of MoonLake Immunotherapeutics
- Dr. Kristian Reich (person) — Member of the company
- 2024-12-31 (date) — Fiscal year end
- 2025-02-26 (date) — Filing date
FAQ
What are MoonLake Immunotherapeutics' primary business segments or therapeutic areas?
The provided excerpt indicates the company's SIC code is 'PHARMACEUTICAL PREPARATIONS [2834]', suggesting a focus on drug manufacturing, but does not detail specific therapeutic areas or business segments.
What were the total revenues and net income for MoonLake Immunotherapeutics in fiscal year 2024?
The provided excerpt does not contain specific financial figures for total revenues or net income for fiscal year 2024.
What are the key risks and uncertainties highlighted in the 10-K filing for MoonLake Immunotherapeutics?
This excerpt does not detail specific risks and uncertainties; however, the pharmaceutical industry generally faces risks related to R&D, regulatory approval, and competition.
Who are the principal executive officers and directors of MoonLake Immunotherapeutics as of December 31, 2024?
Dr. Kristian Reich is mentioned as a member, but a full list of principal executive officers and directors is not provided in this excerpt.
What is the company's cash position and liquidity as of December 31, 2024?
The provided excerpt does not include information on the company's cash position or liquidity.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 26, 2025 by Dr. Kristian Reich regarding MoonLake Immunotherapeutics (MLTX).